Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.
Wang A, Yan XE, Wu H, Wang W, Hu C, Chen C, Zhao Z, Zhao P, Li X, Wang L, Wang B, Ye Z, Wang J, Wang C, Zhang W, Gray NS, Weisberg EL, Chen L, Liu J, Yun CH, Liu Q.
Wang A, et al. Among authors: zhang w.
Oncotarget. 2016 Oct 25;7(43):69760-69769. doi: 10.18632/oncotarget.11951.
Oncotarget. 2016.
PMID: 27626175
Free PMC article.